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Abstract
The authors conducted this study to identify whether bacille Calmette-Gue´rin (BCG) vaccination leads to an altered spectrum of
neuroimaging findings outcome in pediatric patients with tuberculous meningitis. This retrospective study was conducted through
chart review and review of computed tomography (CT) scans and magnetic resonance imaging (MRI) of patients with confirmed
central nervous system tuberculosis from the year 1992 to 2005, at a large tertiary care hospital in Karachi, Pakistan. A total of
108 pediatric patients with tuberculous meningitis were included in the analysis. Of the 108 patients, 63 (58.3%) were male and 45
(41.7%) had received bacille Calmette-Gue´rin vaccination. There was no difference in terms of severity of clinical presentation
and outcome between vaccinated and unvaccinated group. There were no significant differences in CT or MRI findings between
the 2 groups except for tuberculomas on MRI, which were significantly higher in the nonbacille Calmette-Gue´rin vaccinated
group (52.2% vs 22.7%, P ¼ .042). Bacille Calmette-Gue´rin vaccination appears to translate into less tuberculoma formation
on MRI.
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Tuberculosis is one of the leading causes of mortality and
morbidity worldwide. Globally, 9.2 million new cases and
1.7 million deaths from tuberculosis occurred in 2006.1
Pakistan, a developing country in South Asia, is currently the
sixth most populous country in the world with a population
of 172.8 million.2 With an estimated tuberculosis prevalence
of 263 and a resulting mortality of 34 per 100 000 people per
year, tuberculosis is a serious public health problem in
Pakistan.1
Tuberculous meningitis accounts for 5% to 10% of all tuber-
culosis cases but is responsible for more than 40% of the deaths
due to tuberculosis.3 It is more common in children. Tuber-
culous meningitis has proven to be a challenging disease to
diagnose and treat and has received less attention than pulmon-
ary tuberculosis.4
Tuberculous meningitis has a wide variety of presentations. In
a review of 214 children with tuberculous meningitis, fever was
reported in 91%, vomiting in 87%, personality change in 63%,
seizures in 62%, nuchal rigidity in 59%, and headaches in
58%.5 Recent contact with tuberculosis should be elucidated;
several studies have shown that between 66% and 90% of
children have had a recent positive contact.5,6 Neurological
complications include cranial nerve palsies, infarcts, hydro-
cephalus, seizures, tuberculoma, deafness, loss of sphincter con-
trol, and spastic or flaccid paralysis. Computed tomography (CT)
and magnetic resonance imaging (MRI) provide diagnostic infor-
mation at presentation and when complications occur. Findings
such as basal enhancement, hydrocephalus, tuberculoma, and
infarction are more specific for tuberculous meningitis in chil-
dren as compared to other pyogenic meningitis. Meticulous
microscopy followed by culture of >5 mL of cerebrospinal fluid
is recommended. Cerebrospinal fluid smears are positive for
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acid-fast bacilli in about 10% to 20% of those with tubercu-
lous meningitis.7 The culture of Mycobacterium tuberculosis
from the cerebrospinal fluid is the gold standard for diagnosis
but is insensitive and slow even with modern culture tech-
niques. Newer methods of diagnosis include commercial
nucleic acid amplification assays. However, a meta-analysis
showed that at the start of treatment, careful bacteriology is
as good as, or better than, the commercial nucleic acid ampli-
fication assays, but molecular methods may be more useful
when antituberculosis drugs have started.8 In summary, tuber-
culous meningitis requires a high level of suspicion for diag-
nosis. Early diagnosis and prompt treatment cannot be
stressed enough, as a delay in treatment results in either death
or considerable neurological morbidity.9
The bacille Calmette-Gue´rin (BCG) vaccine remains the
cornerstone of the World Health Organization (WHO) tubercu-
losis prevention program in children. Even after eight decades
of use, the efficacy of the bacille Calmette-Gue´rin vaccine is
still shrouded in controversy, with reported protective rates
ranging from 0% to 80% in large epidemiological studies.10-
12 The effect is probably time limited because vaccination dur-
ing infancy does not decrease the incidence of tuberculosis in
adults. Although the bacille Calmette-Gue´rin vaccination is not
highly effective in preventing the illness, it does play a role in
reducing the severity of the more serious forms of the disease
such as disseminated disease and tuberculous meningitis.13,14
There are no reliable data on bacille Calmette-Gue´rin coverage
in our country, but it is estimated to be about 30%. Although the
bacille Calmette-Gue´rin vaccine is a compulsory vaccine in
Pakistan and is included in the national vaccination program, the
coverage is not satisfactory. This is a reality in developing coun-
tries. For example, in the study by Yaramis et al on 214 cases
with pediatric tuberculous meningitis, only 25 patients (12%)
had a history of single bacille Calmette-Gue´rin vaccination.5 The
other children did not receive bacille Calmette-Gue´rin vaccina-
tion. This is despite the presence of bacille Calmette-Gue´rin
vaccination in the routine immunization program of the Turkish
Ministry of Health. It is given as an intradermal injection during
the neonatal period, ideally within the first week after birth.
It is well known that the prognosis of central nervous system
tuberculosis is worse in unvaccinated patients.15-17 Adult
patients with intracranial tuberculoma carry a poor prognosis
as compared to nontuberculoma patients.18 It is still unclear
whether the bacille Calmette-Gue´rin vaccine has any influence
in modifying the radiological features in pediatric patients with
tuberculous meningitis. Only a few studies have explored this
area and have ascertained a clinical and laboratory profile of
such patients. However, neuroimaging findings have not been
studied in depth: only CT scan findings have been looked at
in these studies but not MRI findings. If bacille Calmette-
Gue´rin vaccination does change the clinical and imaging
spectrum of tuberculous meningitis, it is useful to identify
the new features for prognosis of these patients. We conducted
this study to identify whether bacille Calmette-Gue´rin vaccina-
tion leads to an altered spectrum of neuroimaging findings in
pediatric patients with tuberculous meningitis and whether
unvaccinated patients had a more severe form of intracranial
tuberculosis as compared to vaccinated patients.
Methods
This retrospective study was conducted at the Aga Khan University
Hospital, a large tertiary care hospital in Karachi, the largest city of
Pakistan. Aga Khan University Hospital receives patients from all over
Karachi. A data questionnaire was used to collect data via a thorough
chart review of patients from the year 1992 to 2005. The patient records
were identified by the International Classification of Diseases, Ninth
Revision coding system. The study protocol was approved by the Insti-
tutional Ethics Review Committee. Retrospective chart reviews do not
require informed consent for enrollment in a specific study at our insti-
tution. All patients or attendants sign a consent form at the time of
admission permitting data to be used for research without exposing the
identity of the patient. Authors have nothing to disclose as a conflict of
interest. No funding was involved. All authors contributed in data anal-
ysis, manuscript writing, and manuscript review.
All patients with tuberculous meningitis aged 18 years and below
were included. The criteria for tuberculous meningitis diagnosis were
as follows: (1) either positive cerebrospinal fluid culture or positive
biopsy (histopathology) of intracranial lesion or (2) abnormal
cerebrospinal fluid or intracranial lesion with culture-positive or
biopsy-positive pulmonary or nodal tuberculosis. All the patients were
admitted to the hospital and underwent most laboratory and imaging
studies in the same hospital. Two radiologists were involved in review-
ing the imaging scans. Neuropathology (excisional biopsy) specimens
were reviewed by 2 trained pathologists. The diagnosis of tuberculoma
was based on the presence of caseation necrosis with granuloma forma-
tion. Specimens were stained by routine hematoxylin and eosin stain
and special stains such as Ziehl-Neelson stain for acid-fast bacilli and
periodic acid Schiff stain for fungal hyphae. All tuberculomas were
graded for the amounts of fibrosis, gliosis, necrosis, and the cellular ele-
ments (lymphocytes, macrophages, and plasma cells). Either a docu-
mented history of bacille Calmette-Gue´rin vaccination or the
presence of the bacille Calmette-Gue´rin scar were accepted as confir-
mation of bacille Calmette-Gue´rin vaccination, as few people in Paki-
stan keep a vaccination record. Cerebrospinal fluid cultures were
performed using Lowenstein Jensen medium and BACTEC medium
and recently mycobacteria growth indicator tubes medium. None of the
patients underwent gastric aspirates culture because of labor-intense
acid neutralization techniques and poor yield at our center.
Data were entered and analyzed using the Statistical Package for
Social Sciences 16.0 (SPSS, Inc, Chicago, Illinois). Descriptive statis-
tics were performed. Results were recorded as frequencies, means+
standard deviations, and P values. Univariate analysis was done using
the w2 test and Fisher exact test for categorical variables. The indepen-
dent samples t test was used for continuous variables. A P value of
<.05 was taken as the criteria of significance for all purposes.
Results
A total of 192 potential patients were identified. In all, 84 were
excluded because of an unconfirmed diagnosis, nonavailability
of imaging data, and/or lack of proper documentation. A total
of 108 pediatric patients with central nervous system tubercu-
losis were included in analysis. The diagnosis of tuberculosis
was confirmed by positive cerebrospinal fluid culture (n ¼
69) or abnormal cerebrospinal fluid or intracranial lesion with
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culture-positive or biopsy-positive pulmonary or nodal tuber-
culosis (n ¼ 39).The mean age was 6.3+ 4.6 years and about
70% were aged 9 years or less. There was no significant differ-
ence between the mean ages of bacille Calmette-Gue´rin vacci-
nated and unvaccinated patients. Of the 108 patients, 63
(58.3%) were male and 45 (41.7%) had received bacille Calm-
ette-Gue´rin vaccination. The mean duration of hospital stay at
first admission was 12.0+ 10.0 days, with no significant dif-
ference between the 2 groups. The overall outcome was not sta-
tistically different between the 2 groups. Table 1 shows the
baseline characteristics, clinical and laboratory features, and
outcome of the 2 vaccination groups.
Table 2 compares the CT scan findings among the bacille
Calmette-Gue´rin vaccinated patients and the unvaccinated
patients. A total of 71 patients were evaluated with a CT scan,
with 30 in the bacille Calmette-Gue´rin vaccinated group. Of
these, 55 (77%) were postcontrast scans. Overall, the most
frequent finding reported was hydrocephalus (46.5%) followed
by meningeal enhancement (25.4%) and infarction (15.5%).
There were no significant differences between the 2 groups
in terms of CT imaging findings.
Table 3 compares the MRI scan findings among the bacille
Calmette-Gue´rin vaccinated patients and the unvaccinated
patients. A total of 45 patients were evaluated with an MRI,
with 22 in the bacille Calmette-Gue´rin vaccinated group. Of
these, 38 (84%) were postcontrast scans. The rate of enhance-
ment among these patients was 66% (mostly tuberculoma fol-
lowed by meningeal enhancement and cerebritis). Overall, the
most frequent finding reported was tuberculoma (37.5%) fol-
lowed by hydrocephalus (31.1%) and meningeal enhancement
(26.7%). There were no significant differences in MRI findings
between the 2 groups except for the presence of a tuberculoma,
which occurred significantly more often in the unvaccinated
group (52.2% vs 22.7%, P ¼ .042).
Table 1. Characteristics and Outcome of the Patients With Tuberculous Meningitisa
Bacille Calmette-Gue´rin vaccinated
All (n ¼ 108) P ValueYes (n ¼ 45) No (n ¼ 63)
Age (years) 5.6+ 4.4 6.9+ 4.6 6.3+ 4.6 .147
Gender
Male 26 (57.8) 37 (58.7) 63 (58.3) .921
Female 19 (42.2) 26 (41.3) 45 (41.7)
Duration of first admission (days) 12.4 + 9.5 11.8+ 10.4 12.0+ 10.0 .769
Involvement of other sites with TB
Yes 10 (23.8) 10 (17.2) 20 (20.0) .418
Clinical features at presentation
Coma 11 (24) 14 (22) 25 (23) .514
Seizures 19 (42) 23 (36) 42 (39) .491
Hemiparesis 7 (16) 12 (19) 19 (18) .860
Positive CSF culture for AFB 30 (66) 39 (61) 69 (67) .542
Outcome at discharge
Complete recovery 15 (33) 16 (25) 31 (29) .09
With neurological deficits 24 (53) 36 (57) 60 (58) .675
Death 8 (17) 9 (14) 17 (16) .493
Note: AFB, acid-fast bacilli; CSF, cerebrospinal fluid; TB, tuberculosis.
a Percentages in parentheses.
Table 2. Comparison of CT Scan Findings Among Bacille Calmette-Gue´rin-Vaccinated Patients and Unvaccinated Patients
CT Scan Findings
History of Bacille Calmette-Gue´rin Vaccination
All (n ¼ 71)
n (%) P Value
Yes (n ¼ 30) No (n ¼ 41)
n (%) n (%)
Infarction 4 (13.3) 7 (17.1) 11 (15.5) .750
Hydrocephalus 16 (53.3) 17 (41.5) 33 (46.5) .322
Cerebritis 2 (6.7) 7 (17.1) 9 (12.7) .285
Tuberculoma 3 (10.0) 7 (17.1) 10 (14.1) .502
Meningeal enhancement 10 (33.3) 8 (19.5) 18 (25.4) .186
Cerebral edema 4 (13.3) 6 (14.6) 10 (14.1) >.999
Ventriculitis 1 (3.3) 3 (7.3) 4 (5.6) .633
Cerebral atrophy 1 (3.3) 2 (4.9) 3 (4.2) >.999
Note: CT, computed tomography.
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Discussion
The current study has documented the neuroimaging findings
of bacille Calmette-Gue´rin vaccinated and unvaccinated pedia-
tric patients with tuberculous meningitis. No significant differ-
ences exist between the 2 groups in terms of CT scan findings
but when MRI findings are compared, tuberculomas are signif-
icantly more common in the nonbacille Calmette-Gue´rin
vaccinated group. Our study did not show a statistically signif-
icant difference between the 2 groups in terms of severity of
disease at presentation and outcome.
Two earlier studies explored the CT scan findings of bacille
Calmette-Gue´rin vaccinated and unvaccinated patients, but
none has commented on MRI findings. One study is from
Turkey16 and the more recent one is from India,15 a South
Asian developing country like Pakistan.
There were no significant differences between the ages of
the bacille Calmette-Gue´rin vaccinated and unvaccinated
patients in either of the 2 studies. This is concordant with our
findings. However, the mean age of patients in both groups was
higher in our study population when compared to the 2 studies:
vaccinated group (5.6 years vs 3.9 [Indian] and 4.1 years [Turk-
ish]) and unvaccinated group (6.9 years vs 3.8 [Indian] and 4.4
years [Turkish]). This implies that bacille Calmette-Gue´rin
vaccination has no effect on the age at which tuberculous
meningitis develops. However, our study indicates that tuber-
culous meningitis manifests itself at an older age in Pakistan,
as compared to other countries. We do not have an explanation
for this difference. This difference in ages could be due to sam-
pling bias or difference in vaccination coverages or nutritional
status of patients. In a study by Yaramis et al, age ranged from
3 months to 15 years, with a mean age of 4.1 years; 77% of the
children were younger than 5 years and 44% of the patients
were between 12 and 24 months of age.5 Jamieson’s study did
not mention the mean age but only mentioned that Red Cross
Children’s Hospital treats children up to 12 years of age.19
Patients in our series were older than those in Yaramis’ series,
which is in agreement with their observations.
Bacille Calmette-Gue´rin vaccination had no effect on the
length of hospital stay, similar to the findings by Kumar
et al.15 Our patients’ hospital stay was almost half that reported
by an Indian study15: bacille Calmette-Gue´rin vaccinated group
(12.4 days vs 22.3 days) and unvaccinated group (11.8 vs 20.7).
One plausible explanation is that our study population pre-
sented at earlier stages of tuberculous meningitis than patients
in the Indian study and hence recovered faster. Alternatively,
the criteria for discharge may have been different in the Indian
study.
When the CT scan findings in our study were compared to
those in the 2 studies, hydrocephalus was the most common
finding in all 3 studies (46.5% vs 97.9%-100% [Indian] and
63.5% [Turkish]). However, it was found in less than half the
patients in our study compared to the Indian study where
almost all the 150 patients had hydrocephalus. This observation
suggests that the patients were sicker in the Indian study. The
next most common finding in all the 3 studies was basilar
meningeal enhancement (25.3% vs 81.4-84.3% [Indian] and
29.9% [Turkish]). Again, it is noted that basilar meningeal
enhancement was 3 times more commonly found in the Indian
study when compared to the current study.
There were no significant differences in the CT scan find-
ings between the bacille Calmette-Gue´rin vaccinated and
unvaccinated group. This was also the case in the Indian study,
but Guler et al reported that tuberculomas were observed more
frequently in the unvaccinated group (P < .02).16 This study
was based on CT scan findings only. One study comparing
CT scan and MRI concluded that CT scans were more sensitive
in diagnosing calcification, whereas MRI scans were more sen-
sitive in picking up tuberculomas, infarcts, and meningeal
enhancement.20 Calcification is rarely seen in tuberculomas.
Intracranial tuberculomas are histologically composed of
caseating granulomatous tissue and result from hematogenous
spread from a systemic tuberculous infection.3 They may occur
as isolated space-occupying lesions or may coexist with tuber-
culous meningitis. It is reported that tuberculomas are less
frequently observed in human immunodeficiency virus
Table 3. Comparison of MRI Findings Among Bacille Calmette-Gue´rin-Vaccinated Patients and Unvaccinated Patients
MRI Findings
History of Bacille Calmette-Gue´rin Vaccination
All (n ¼ 45)
P Value
Yes (n ¼ 22) No (n ¼ 23)
n (%) n (%) n (%)
Infarction 4 (18.2) 4 (17.4) 8 (17.8) >.999
Hydrocephalus 8 (36.4) 6 (26.1) 14 (31.1) .457
Cerebritis 3 (13.6) 0 (0) 3 (6.7) .109
Tuberculoma 5 (22.7) 12 (52.2) 17 (37.8) .042
Meningeal enhancement 5 (22.7) 7 (30.4) 12 (26.7) .559
Cerebral edema 1 (4.5) 3 (13.0) 4 (8.9) .608
Myelitis 1 (4.5) 0 (0) 1 (2.2) .489
Ventriculitis 1 (4.5) 0 (0) 1 (2.2) .489
Cerebral atrophy 0 (0) 2 (8.7) 2 (4.4) .489
Note: MRI, magnetic resonance imaging.
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(HIV)-infected patients than non-HIV-infected patients. This
observation had led to the hypothesis that tuberculomas form
because of a robust immunological response to tuberculous
infection. A study of adult patients with intracranial tubercu-
loma from our center reported that multiple tuberculomas and
infratentorial lesions were more common in our population as
compared to previous reports.20 In the current study, 17
(37.8%) children had tuberculomas detected by MRI on admis-
sion and 10 (14.1%) by CT scan. We did not include tubercu-
lomas that developed as a paradoxical response after starting
antituberculous therapy. The frequency of tuberculomas in
children in our study is much higher than that reported in the
literature: Jameison reported tuberculoma frequency as 10%
in his study19 and Yaramis et al5 reported a frequency of 2%
in their 214 cases with pediatric tuberculous meningitis. In
addition, Yaramis et al reported that tuberculomas may be more
common in older children, and basilar meningitis and hydroce-
phalus more common in younger children.
Our study did not show a statistically significant difference
between the 2 groups in terms of severity of disease at presen-
tation and outcome. We do not have a clear explanation for
these findings but it is possible that vaccinated people mount
a strong immunological response leading to eradication of
intraparenchymal infection as compared with unvaccinated
participants where infection is sealed off but not eradicated
by the immune system. It is our observation that the presence
of tuberculoma on imaging represents a more severe form of
central nervous system tuberculosis as compared to patients
with tuberculous meningitis without tuberculoma. Patients with
tuberculoma have more neurological disability and require lon-
ger treatment mainly due to parenchymal involvement, while in
tuberculous meningitis, the disease is largely limited to
meninges. We postulate that tuberculoma formation in central
nervous system tuberculosis is probably representative of a
defective immune response where infection is not eradicated,
but contained.
Overall, having received bacille Calmette-Gue´rin vaccina-
tion correlated with a lower likelihood of tuberculoma forma-
tion on MRI or less severe form of central nervous system
tuberculosis. The mechanism of this decreased tuberculoma
in vaccinated patients is not well understood. These findings
may provide a basis for the previous findings that unvaccinated
patients have a more severe form of central nervous system
tuberculosis with more complications and sequelae.
A few caveats have to be borne in mind before interpreting
the results of this study. The immune status of these patients,
including their HIV status, was not known. About 10% to
15% of bacille Calmette-Gue´rin vaccinated patients do not
develop scars at the injection site. In the absence of documen-
tation of vaccination, these patients may have been included in
the unvaccinated group. The quality of vaccination is also ques-
tionable in rural areas. Being a retrospective study, it had
an inherent limitation; precise data about the duration of illness
before presentation, Glasgow Coma Scale value, or tuberculous
meningitis stage at presentation and other relevant characteris-
tics could not be collected.
Conclusion
Bacille Calmette-Gue´rin vaccination appears to translate into
less tuberculoma formation on MRI. There were no other sig-
nificant differences found in CT or MRI scan abnormalities
between bacille Calmette-Gue´rin vaccinated and unvaccinated
group. As a whole, neuroradiological findings of tuberculous
meningitis are not much affected by bacille Calmette-Gue´rin
vaccination. Further studies with a larger sample size may be
required to confirm this.
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